CCS1477, a first-in-class small molecule to treat prostate (CRPC) and other cancers

P300/CBP bromodomain inhibitor CCS1477

Our science

CCS1477 inhibits the bromodomains of twin histone acetyl transferase proteins, p300/CBP

There is a large and growing population of prostate cancer patients that are resistant to second generation anti-hormonal drugs. CCS1477 addresses this through lowering the key drivers of this resistance and late stage disease: AR, AR-SV and c-Myc.

Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological, bladder and lung cancers.

Backed by strong pre-clinical data, CCS1477 is now heading to clinical trials.

CellCentric’s scientific foundation is in epigenetics. Having originally spun out of the University of Cambridge, the company has investigated over 50 epigenetic-related targets before focusing on p300/CBP.
More on CCS1477

Our team

CellCentric’s team has deep experience of drug discovery and development in oncology

The company is supported by a strong network of clinical, scientific and commercial advisors. CellCentric also actively collaborates with a number of world-leading cancer research centres, on the effects of CCS1477 and p300/CBP inhibition.

Press releases
See more

Twitter
(Follow us)

CellCentric will be pursuing p300/CBP inhibitor CCS1477 for Haem cancers, as well as prostate. pic.twitter.com/ELLi9ZEwOP

Further clinical site initiated: Ruth Plummer and team, Newcastle. CCS1477 for prostate and other cancers. pic.twitter.com/1kN6BVZGQL

CCS1477: unusual duration of effect after dosing cessation; sustained tumour suppression, prolonged low PSA pic.twitter.com/7whtWlw4Xy

Nigel attending the Institute of Cancer Research, Johann de Bono celebratory lecture, London. pic.twitter.com/bvk3mszvhW